Atlas Trials

Dose Escalation Study to Evaluate Safety and Tolerability of an Allogeneic Tumor Vaccine BIWB 2 in Patients With Advanced Malignant Melanoma

Clinical trial NCT02203864 · COMPLETED

Trial details

NCT number
NCT02203864
Sponsor
Boehringer Ingelheim
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Melanoma
Start date
1998-08-01
Primary completion
2001-02-01
Enrollment
49

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.